Scynexis Stock News

JERSEY CITY, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resist

SCYNEXIS (SCYX) granted stock options and Restricted Stock Units to five new employees; grants consists of 41K shares exercisable at $4.9/share.Each option has a 10-year term,…

JERSEY CITY, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resist

Scynexis Inc (SCYX) shares closed today 10.6% higher than it did at the end of yesterday. The stock is currently down 0.8% year-to-date, down 23.3% over the past 12 months, and down 83.1% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $6.30 and as low as $5.41 this week.Shares closed 41.0% below its 52-week high and 23.5% above its 52-week low.Trading volume this week was 16.4% lower than the 10-day average and 16.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -92.1% The company's stock price performance over the past 12 months lags the peer average by -271.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Scynexis Inc (SCYX) shares closed today 10.6% higher than it did at the end of yesterday. The stock is currently down 0.8% year-to-date, down 23.7% over the past 12 months, and down 83.1% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $6.30 and as low as $5.41 this week.Shares closed 41.0% below its 52-week high and 23.5% above its 52-week low.Trading volume this week was 6.6% lower than the 10-day average and 16.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 4.9% higher than its 5-day moving average, 5.3% lower than its 20-day moving average, and 0.6% lower than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -91.7% The company's stock price performance over the past 12 months lags the peer average by -279.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

JERSEY CITY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resist

JERSEY CITY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan

JERSEY CITY, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resist

A novel first-in-class, one-day oral antifungal treatment, BREXAFEMME is now covered for more than 45% of commercially insured patients in the U.S. A novel first-in-class, one-day oral antifungal trea

JERSEY CITY, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resist

JERSEY CITY, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to ibrexafungerp for the indication of invasive candidiasis (IC).

JERSEY CITY, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced initiation of a global Phase 3 study to evaluate the efficacy, safety and tolerability of oral ibrexafungerp as a step-down therapy for patients with invasive candidiasis and/or candidemia following intravenous (IV) echinocandin therapy in the hospital compared to currently-available outpatient therapies.

JERSEY CITY, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resist

JERSEY CITY, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced grants of stock options to two new employees to purchase an aggregate of 5,200 shares of SCYNEXIS common stock at a per share exercise price of $7.38, the closing trading price on November 30, 2021. The stock options were granted as material inducements to the new employees to accept SCYNEXIS offers of employment.